

Medmarc Casualty Insurance Company
ProAssurance Specialty Insurance Company
Life Sciences
Products and Completed Operations Liability Insurance

A ProAssurance Company

4795 Meadow Wood Lane Suite 335 West Chantilly, VA 20151-2219 Phone: 703-652-1300 Toll free: 1-800-356-6886

Fax: 703-652-1389 Email: apps@medmarc.com

Renewal Application

This application is for a Claims Made policy.

- Please answer all questions completely, using attachments if necessary.
- Do not leave any space blank. Please indicate "n/a" if a question is not applicable.
- If there is insufficient space to answer a question, please attach additional pages.
- Please attach current financial information for any privately-held company.

1	PRODUCTS	COMPLETED	OPERATIONS	RENEWA!
	FRUDULIS	CUIVIPLETED	OPERATIONS	INCINEVVAL

Current Insurance Information			
14. Desired limits, if different from current limit:			
15. Desired self-insured retention or deductible, if differential	rent from current:		
16. Does your firm currently carry excess liability covera	nge? □ Yes	□ No	
If yes, please provide the coverage information requested belo	DW.		Claims Made
Carrier Limit	Coverage		Retro Date
			1161.0 2 4.00
17. May we provide you with quotes for other lines of c	overage?		
☐ Excess Liability		☐ Standa	rd Lines*
*If you are interested in standard lines of coverage (CGL, Auto	, Property, Workers' Coi		
partner, Pharmacists Mutual, please submit an ACORD applica		•	,
Projected Revenue Information		(4)	- (4)
	U.S./Canada revenu	e (\$)	Foreign revenue (\$)
Proprietary medical device manufacturing			
Proprietary pharmaceutical/biologic manufacturing			
Contract manufacturing			
Contract services for others (e.g., packaging,			
repackaging, sterilization, regulatory)			
Specification development			
Distribution			
Importing for distribution			
Equipment rental			
Installation/maintenance/repair/servicing			
Research and development			
Consulting/design services			
Other			
If other, please describe.			
Product Information			
18. Have there been any changes to your existing produ	icts or operations sinc	e last year?	
☐ Yes	□ No		
If yes, please describe.			
40.5			
19. Do you have products under development or in clini		xpect to intro	duce during the policy term?
☐ Yes	□ No		
If yes, please describe.			
20. Have any products been discontinued in the last year	nr?		
☐ Yes	□ No		
If yes, please list discontinued products and the reason(s) for a			
Product	Reason		
rroduct	Neuson		

PCOR EONR Rev. 11/11/22 Page **2** of **13**

21. Do you m	21. Do you manufacture any new products for others to sell under their labels?					
	<u> </u>			lo		
22. Do you se	II any ne	w products manufa	actured by others unde	r your label?		
	Y	'es		lo		
Regulatory Hi						· .
			FDA registration in the	past year (e.g. n	io longer registered, dif	terent or
additional	_	tions, etc.)?				
	☐ Yes	S	□ No			
If yes, please de	escribe.					
24 Have any	of vour r	aradusts baan rame	wad ar racallad from th	no market in the	last year?	
24. Have ally			oved or recalled from th		iast year!	
	☐ Ye		□ N	0		
If yes, please co	-			_		
Recall Date	Class	Product		Reason		Closed?
						☐ Yes ☐ No
						☐ Yes ☐ No
25. Has FDA visited your facilities in the last year?						
	□ Ye	es	\square N	0		
If you received	an FDA Fo	orm 483 during this ti	me period, please attach	copies of the 483 a	and your response to FDA.	
			etter in the last year?			
,	□ Ye	_	, □ N	0		
If ves inlease at			tter and your response to			
			r self-audit, or has one		for you by a third party	/ in the last year?
27. Have you	□ Ye			•	ior you by a tima party	,, iii tiic iast year:
16				O		
		opy of the audit repo		C or other signif	icant cafety warning?	
26. DO ally Of	your pro		ack box warning," REM		icani salety warning:	
If you plaged at			∟ וע REMS materials, or other		warning not proviously s	unnlied to us
			issued any of the follo			ipplied to us.
25. 111 the last	. year, na	ive you reported or	issued arry of the folio	willig: Check un th	ит ирргу.	
☐ MDRs or a	dverse e	vent reports	Public health not	ification or	☐ Dear Doctor/Hea	althcare
			field/safety alert	S	Practitioner lette	ers
30. In the last year, have you had any Serious Adverse Events ¹ that have not been reported to us or a previous insurer?						
☐ Yes ☐ No						
If yes, please at	tach desc	riptions of the unrep	orted SAEs.			
<u> </u>	· · · · · · · · · · · · · · · · · · ·					

PCOR EONR Rev. 11/11/22 Page **3** of **13**

¹ **Serious Adverse Event** means an undesirable experience associated with your product where the outcome to the patient:

⁽a) is life threatening;

⁽b) is death;

⁽c) required hospitalization (initial or prolonged);

⁽d) is disability or permanent damage;

⁽e) is a congenital anomaly or birth defect;

⁽f) required intervention to prevent permanent impairment or damage; or

⁽g) required medical intervention to prevent one of the outcomes (a) through (f) above.

Human Clinical Trial History	
Check box if no changes below in this section. \Box	
31. Are you using a contract research organization (CRO) in ☐ Yes ☐ No	any of your studies?
32. Do you use HHS-registered institutional review boards (IRBs)?	If no, please explain.
☐ Yes ☐ No	
33. Do you use indemnification agreements with investigators, IRBs, and CROs? ☐ Yes ☐ No	If no, please explain.
34. Have any of your IRBs, investigators, or clinical sites received a Warning Letter or been the subject of an adverse FDA action? ☐ Yes ☐ No	If yes, please explain.
35. Have you or your investigator ever been cited, debarred, fined, or suspended?	If yes, please explain.
36. Have any trials been discontinued or suspended for safety reasons, whether by you, FDA, or another authority?	If yes, please explain.
37. Have any subjects had a serious adverse event (life-threatening, death, hospitalization, disability or permanent damage, congenital anomaly or birth defect, or required intervention to prevent one of these outcomes)? ☐ Yes ☐ No	If yes, please explain.
38. Do any of your trials involve subjects who are members of a "vulnerable"² patient population? ☐ Yes ☐ No	If yes, please explain.
39. Are you planning any foreign clinical trials during the policy term? ☐ Yes ☐ No	If yes, please explain.
40. Are you sponsoring any clinical trials in which you have invited your own employees to participate? ☐ Yes ☐ No	If yes, please explain.
41. Are any investigator-sponsored trials using your product? ☐ Yes ☐ No	If yes, please explain.
42. Are any of your investigational (i.e., unapproved) drugs or devices accessible to seriously ill test subjects who are not candidates for clinical trials?	If yes, please explain.
43. Do you export drugs for patients in foreign markets before those drugs have received marketing approval in the U.S.?	If yes, please explain.

PCOR EONR Rev. 11/11/22 Page **4** of **13**

² "Vulnerable" patients include children, prisoners, pregnant women, handicapped or mentally-disabled persons, or economically or educationally-disadvantaged persons, as defined by 21 CFR 56.111(3).

Human Clinical Trial Sponsorship and Funding		
Check box if no changes below in this section. \Box		
44. Is the named insured the trial sponsor?		
☐ Yes	□ No	
If no, please explain.		
45. How are your clinical trials funded?		
Source		Amount

Continue to the next page.

46. Please	list clinical tr	ials that a	re ongoing or anticipat	ed during	the policy to	erm. Attach a	copy of	the Proto	ocol(s) an	d Informed Conse	nt Form(s) f	or each.
Protocol: Number & Name	Type of Trial ³	Risk Level ⁴	Product Name & Description	Trial Phase	Total Subjects Projected	Subject Enrollment Policy Ter Past 12 mo Next 12 mo	t for erm os./	Trial Start,		FDA Classification for Trial Status ⁵	Number of Trial Sites	Trial Locations
		□ SR										□ Foreign
		□ NSR										☐ Domestic
		☐ Drug										□ Both
		□ SR										□ Foreign
		□ NSR										☐ Domestic
		☐ Drug										□ Both
		□ SR										□ Foreign
		□ NSR										☐ Domestic
		☐ Drug										□ Both
Please attac	ch a list of any	additional	clinical trials.		•					•	•	

³ Type of Trial

Human Clinical Trial Log

Treatment trial – tests experimental treatments, new combinations of drugs, or new approaches to surgery or radiation therapy

• Prevention trial – looks for better ways to prevent disease in people who have never had the disease, or to prevent a disease from returning. These approaches may include medicines, vaccines, vitamins, minerals, or lifestyle changes.

• Diagnostic trial – conducted to find better tests or procedures for diagnosing a particular disease or condition

• Screening trial – tests the best way to detect certain diseases or health conditions

• Quality of Life trial (or Supportive Care trials) – explores ways to improve comfort and the quality of life for individuals with a chronic illness

• Registry trial – observational studies in which the events that happen to test subjects with a specific disease or condition are recorded without pre-defined treatment

- Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject;
- Is purported or represented to be for use supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject;
- Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject; or
- Otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.

All other devices are considered to be of Nonsignificant Risk (NSR).

- Pending not yet recruiting
- Ongoing recruiting and enrollment completed; study proceeding according to or ahead of schedule
- Delayed study behind schedule
- Withdrawn study halted prematurely prior to enrollment of the first participant
- Suspended recruiting or enrolling participants has halted prematurely but potentially will resume
- Terminated study halted prematurely and will not resume; participants are no longer being examined or treated
- Completed study has concluded normally; participants are no longer being examined or treated

PCOR EONR Rev. 11/11/22 Page **6** of **13**

⁴ FDA defines a Significant Risk **(SR)** Device as a device that:

⁵ FDA classifications for trial status:

Claim/Incident Information		
	imstance(s) which may recult in a alai	im against you under the source
47. List any unreported incident(s) and/or circu	anistance(s) which may result in a clai	iiii against you under the coverage
requested in this application.		
II. OPTIONAL COVERAGE: MANUFACT	TURERS' FRRORS AND OMISSIO	ONS ⁶
If you wish to renew or purchase Manufacturers' Eri		plete this section. If this coverage is not
desired, please skip to page 11 to complete the app	lication.	
THIS APPLICATION IS FOR:	☐ New Business	☐ Renewal
Current Errors & Omissions Insurance Informa	tion	
For New Business, please complete the entire		
For Renewal, please review questions 51 and 5		
48. Current insurance company:	32 and complete if applicable.	
	0	Claima Manda
	Occurrence	☐ Claims Made
50. Policy renewal date:		
51. Current limit of insurance:		
Provide desired limits, if different from current limit.		
52. Current self-insured retention or deductible	e:	
Provide desired self-insured retention or deductible,	if different from current.	
53. Current retroactive date (if claims made):		
If more than one, please attach current schedule of	retroactive dates.	
Product or Service Information		
Check box if no changes below in this section.		
54. What is the acceptable downtime for your	☐ No downtime is acceptable	
product/service according to your	☐ 1 day or less	
average customer's needs?	☐ 2 days or less	
	☐ 3 days or less	
55. What is the worst negative consequence	a succession less	
that could happen to your customers'		
operations if your products/services were		
to fail or stop working?	to for others' finished and interest	
56. Are any of your products sold as componer	-	
☐ Yes	□ No	

PCOR EONR Rev. 11/11/22 Page **7** of **13**

⁶ Manufacturers' Errors and Omissions is a Claims Made and Reported policy, available on ProAssurance Specialty (non-admitted) only.

Check box if no changes below in this section. \Box						
57. Who are your five largest customers?	Size of Contract	Duration of Contract				
58. Are your products used in:						
a. Clinical trials	□ Yes □ No					
b. Research/laboratory settings	☐ Yes ☐ No					
c. Hospitals/medical facilities	☐ Yes ☐ No					
Quality Control, Training, and Support						
Check box if no changes below in this section.						
59. What certifications do you maintain in the	☐ ISO 13485					
U.S. or in other markets?	☐ ISO 9001					
	☐ CE Mark					
	☐ Underwriters Laboratory (UL)					
	☐ Other:					
60. What professional arganization						
60. What professional organization memberships does your company						
maintain?						
61. Do you have a written procedure for initiation	ng, conducting, and/or complying with	n product recalls?				
☐ Yes	□ No					
62. Do you have a records retention policy for the ☐ Yes	he products you manufacture, sell, or $\hfill \Box$ No	service?				
63. Do you have a documented training plan for	employees, contractors, distributors	and/or end users of your products?				
☐ Yes	□ No	□ N/A				
64. Do you install, customize, or service your pr						
Yes	□ No					
65. Do others install, customize or service your products?	□ Yes □	l No				
a. If yes, do you provide formal training?	☐ Yes ☐	l No				
b. Written instructions?		l No				
c. Sign off on the final product?		l No				
d. Require liability insurance for those insta or servicing your products?	alling ☐ Yes ☐	l No				
66. Do you have contingency plans to service a	customer who experiences a critical fa	ailure of your product or service?				
☐ Yes		, , , , , , , , , , , , , , , , , , , ,				
If yes, please provide a copy of the contingency plan.						
67. Do you provide service and repair of products other than your own?						
☐ Yes ☐ No						
a. If yes, what percentage of total service revenue generated by this work?%						

PCOR EONR Rev. 11/11/22 Page **8** of **13**

Check box if no changes below in this section.				
68. What percentage of your component parts are supplied by outside vendors? 69. What percentage of your component parts are supplied by foreign-based companies? 70. Do you ever agree to hold harmless any suppliers for claims arising out of their products? Yes	Suppliers			
parts are supplied by outside vendors? 69. What percentage of your component parts are supplied by foreign-based companies? 70. Do you ever agree to hold harmless any suppliers for claims arising out of their products? Yes	Check box if no changes below in this section.	3		
parts are supplied by outside vendors? 69. What percentage of your component parts are supplied by foreign-based companies? 70. Do you ever agree to hold harmless any suppliers for claims arising out of their products?	, , , ,	%	Please list vendors:	
parts are supplied by foreign-based companies? 70. Do you ever agree to hold harmless any suppliers for claims arising out of their products? Yes	· · · · · · · · · · · · · · · · · · ·			
companies? 70. Do you ever agree to hold harmless any suppliers for claims arising out of their products? Yes			Please list countries:	
70. Do you ever agree to hold harmless any suppliers for claims arising out of their products? Yes	1	%		
Yes	companies?			
If yes, please explain.	70. Do you ever agree to hold harmless any supp	oliers for claims a	rising out of their products?	
71. Do you require Certificates of Insurance from your suppliers? Yes	☐ Yes	□ No		
Yes No	If yes, please explain.			
Yes No				
Yes No	71 Do you require Certificates of Insurance from	vour suppliers?		
Contracts Check box if no changes below in this section. 72. Does your legal counsel review and approve all contracts, advertising, and promotional materials and brochures? Yes No No 73. Do you require your customers to sign written agreements that outline the specification of products and services you will provide? Yes No No If yes, please provide a sample contract. 74. Do all of your contracts include the following clauses? a. Force majeure Yes No b. Disclaimer of warranties Yes No c. Limitation of liabilities Yes No i. If yes, in what amount? d. Exclusion for consequential damages Yes No e. Customer acceptance of interim changes and final product f. Hold harmless provision Yes No				
Contracts Check box if no changes below in this section. 72. Does your legal counsel review and approve all contracts, advertising, and promotional materials and brochures? Yes			Amount: ¢	
Check box if no changes below in this section. 72. Does your legal counsel review and approve all contracts, advertising, and promotional materials and brochures? Yes	ij yes, what limits of hability do you require?		Amount. \$	_
Check box if no changes below in this section. 72. Does your legal counsel review and approve all contracts, advertising, and promotional materials and brochures? Yes	Contracts			
72. Does your legal counsel review and approve all contracts, advertising, and promotional materials and brochures? Yes				
☐ Yes ☐ No 73. Do you require your customers to sign written agreements that outline the specification of products and services you will provide? ☐ Yes ☐ No If yes, please provide a sample contract. 74. Do all of your contracts include the following clauses? a. Force majeure ☐ Yes ☐ No b. Disclaimer of warranties ☐ Yes ☐ No c. Limitation of liabilities ☐ Yes ☐ No i. If yes, in what amount? \$ d. Exclusion for consequential damages ☐ Yes ☐ No e. Customer acceptance of interim changes and final product ☐ Yes ☐ No f. Hold harmless provision ☐ Yes ☐ No	Check box if no changes below in this section.			
73. Do you require your customers to sign written agreements that outline the specification of products and services you will provide? Yes	72. Does your legal counsel review and approve a	II contracts, adve	ertising, and promotional mat	erials and brochures?
will provide? Yes	☐ Yes	□ No		
will provide? Yes	73. Do you require your customers to sign writter	agreements tha	it outline the specification of	products and services you
☐ Yes ☐ No If yes, please provide a sample contract. 74. Do all of your contracts include the following clauses? a. Force majeure ☐ Yes b. Disclaimer of warranties ☐ Yes c. Limitation of liabilities ☐ Yes i. If yes, in what amount? d. Exclusion for consequential damages ☐ Yes e. Customer acceptance of interim changes and final product ☐ Yes f. Hold harmless provision ☐ Yes		J	·	•
If yes, please provide a sample contract. 74. Do all of your contracts include the following clauses?	·	□ No		
74. Do all of your contracts include the following clauses? a. Force majeure				
a. Force majeure		clauses?		
b. Disclaimer of warranties			☐ Yes	□ No
c. Limitation of liabilities	-			
i. If yes, in what amount? d. Exclusion for consequential damages e. Customer acceptance of interim changes and final product f. Hold harmless provision yes No No				_
d. Exclusion for consequential damages				
e. Customer acceptance of interim changes and	1. II VPS. III WHOI OHIODHII F		Υ	
final product f. Hold harmless provision				□ No
f. Hold harmless provision	d. Exclusion for consequential damages	ges and	☐ Yes	
	d. Exclusion for consequential damagese. Customer acceptance of interim changes	ges and	☐ Yes	
	 d. Exclusion for consequential damages e. Customer acceptance of interim chanfinal product 	ges and	☐ Yes ☐ Yes	□ No
h. Payment terms	 d. Exclusion for consequential damages e. Customer acceptance of interim chanfinal product f. Hold harmless provision 	ges and	☐ Yes ☐ Yes	□ No

Continue to the next page.

PCOR EONR Rev. 11/11/22 Page **9** of **13**

Histo	rical Information					
Chec	k box if no changes below in this section. \square					
infor	If you answer "Yes" to any of the questions in this section, please list all occurrences and include the following information: (1) date of incident; (2) description of issue; (3) remediation made; and (4) any associated financial settlement/judgment and the amount. Please attach an additional sheet if more space is needed.					
	the last year:					
a.	Have any of your customers had a financial loss because of a problem related to your product or service?	If yes, please describe.				
<u> </u>						
b.	Have you had any repeated verbal or written complaints from your customers that were not easily remedied?	If yes, please describe.				
	☐ Yes ☐ No					
C.	Have there been any problems with below standard performance of your products or services, whether or not a complaint was made?	If yes, please describe.				
d.	Have you had a customer stop payment or request a refund because of a product or service problem in the last three years?	If yes, please describe:				
e.	Have you had a customer bring suit or threaten to bring suit because of a problem with your product or service?	If yes, please describe:				

Continue to the next page.

PCOR EONR Rev. 11/11/22 Page **10** of **13**

Insurance Fraud Warnings and Important Notices

For your protection, the following warning is required by various state laws: any person who knowingly and with the intent to injure, defraud, or deceive any insurance company or other person, files a statement of claim or an application containing any false, incomplete or misleading information is guilty of a crime and may be subject to criminal and civil penalties, which may include imprisonment, fines, and denial of insurance.

State Specific Fraud Warning Statements

ALABAMA

Any person who knowingly presents a false or fraudulent claim for payment of a loss or benefit or who knowingly presents false information in an application for insurance is guilty of a crime and may be subject to restitution fines or confinement in prison, or any combination thereof.

ARKANSAS / DISTRICT OF COLUMBIA / LOUISIANA / RHODE ISLAND / WEST VIRGINIA

Any person who knowingly presents a false or fraudulent claim for payment of a loss or benefit or knowingly presents false information in an application for insurance is guilty of a crime and may be subject to fines and confinement in prison.

CALIFORNIA

For your protection California law requires the following to appear on this form:

Any person who knowingly presents false or fraudulent information to obtain or amend insurance coverage or to make a claim for the payment of a loss is guilty of a crime and may be subject to fines and confinement in state prison.

COLORADO

It is unlawful to knowingly provide false, incomplete, or misleading facts or information to an insurance company for the purpose of defrauding or attempting to defraud the company. Penalties may include imprisonment, fines, denial of insurance, and civil damages. Any insurance company or agent of an insurance company who knowingly provides false, incomplete, or misleading facts or information to a policyholder or claimant for the purpose of defrauding or attempting to defraud the policyholders or claimant with regard to settlement or award payable from insurance proceeds shall be reported to the Colorado Division of Insurance within the Department of Regulatory Agencies.

FLORIDA

Any person who knowingly and with intent to injure, defraud, or deceive any insurer files a statement of claim containing any false, incomplete, or misleading information is guilty of a felony of the third degree.

KENTUCKY

Any person who knowingly and with intent to defraud any insurance company or other person files an application for insurance containing any materially false information or conceals, for the purpose of misleading, information concerning any fact material thereto commits a fraudulent insurance act, which is a crime.

.....

MAINE / TENNESSEE / VIRGINIA / WASHINGTON

It is a crime to knowingly provide false, incomplete or misleading information to an insurance company for the purpose of defrauding the company. Penalties may include imprisonment, fines, or denial of insurance benefits.

MARYLAND

Any person who knowingly or willfully presents a false or fraudulent claim for payment of a loss or benefit or who knowingly or willingly presents false information in an application for insurance is guilty of a crime and may be subject to fines and confinement in prison.

NEW JERSEY

Any person who includes any false or misleading information on an application for an insurance policy is subject to criminal and civil penalties.

NEW MEXICO

Any person who knowingly presents a false or fraudulent claim for payment of a loss or benefit or knowingly presents false information in an application for insurance is guilty of a crime and may be subject to civil fines and criminal penalties.

NEW YORK

Fraud Warning

Any person who knowingly and with intent to defraud any insurance company or other person files an application for insurance or statement of claim containing any materially false information, or conceals for the purpose of misleading, information concerning any fact material thereto, commits a fraudulent insurance act, which is a crime and shall also be subject to a civil penalty not to exceed five thousand dollars and the stated value of the claim for each such violation.

IMPORTANT NOTICE

In the event you are applying for claims-made coverage, please note the following important information. the information provides you with important guidance in the event your purchase claims-made coverage from us.

- 1. This is a claims-made policy.
- 2. This policy subject to its terms and conditions:
 - a. applies only to any clam first made against the insured during the policy period or any applicable Extended Reporting Period; and
 - b. does not apply to any claim first made against the insured after the policy period or any applicable Extended Reporting Period or reported after coverage termination.
- 3. This policy provides no coverage for claims arising out of Occurrences which took place prior to any Retroactive Date shown in the policy.
- 4. During the first several years of a claims-made relationship, claims made rates are comparatively lower than occurrence rates. The insured can expect substantial annual premium increases, independent of overall rate level increases, until the claims made relationship reaches maturity.
- 5. All coverage for the policy ceases upon the policy termination date, except for the sixty (60) day automatic Basic Extended Reporting Period, unless an additional Supplemental Extended Reporting Period is purchased.
- 6. A Supplemental Extended Reporting Period of five (5) years is available for purchase upon the payment of additional premium. Potential coverage gaps may arise upon expiration of the Extended Reporting Period. Within thirty (30) days after policy termination, we will send you written notice describing the Basic Extended Reporting Period, the availability of, and the premium for, and the importance of purchasing additional Extended Reporting Period coverage. You must send us a written notice requesting the Supplemental Extended Reporting Period endorsement within the greater time period of ninety (90) days after termination of coverage or thirty (30) days from our mailing or delivery date of the notice for the Supplemental Extended reporting Period.
- 7. The rates for the Supplemental Extended Reporting Period will be based upon the rates in effect at the time of coverage termination. Such rates may be subject to substantial increase over the rates currently in effect and such rates may or may not be indicative of future rate changes. Upon your written request, we will provide you with the average statewide percentage changes and the effective date of each rate revision for this particular type of insurance which we have implemented in the state of New York during the five-year period immediately preceding the effective date of the policy.

ОНЮ

Any person who, with intent to defraud or knowing that he is facilitating a fraud against an insurer, submits an application or files a claim containing a false or deceptive statement is guilty of insurance fraud.

OKLAHOMA

WARNING: Any person who knowingly, and with intent to injure, defraud or deceive any insurer, makes any claim for the proceeds of an insurance policy containing any false, incomplete or misleading information is guilty of a felony.

OREGON

Any person who knowingly and with intent to defraud any insurance company or another person files an application for insurance or statement of claim containing any materially false information, or conceals for the purpose of misleading information concerning any fact material thereto, may be committing a fraudulent insurance act, which may be a crime and may subject the person to criminal and civil penalties.

PENNSYLVANIA

Any person who knowingly and with intent to defraud any insurance company or other person files an application for insurance or statement of claim containing any materially false information or conceals for the purpose of misleading, information concerning any fact material thereto commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

PCOR EONR Rev. 11/11/22 Page **12** of **13**

The undersigned authorized officer of the applicant warrants that the statements set forth in this Application are true and complete, and acknowledges and understands that the Medmarc Casualty Insurance Company and its affiliated company, ProAssurance Specialty Insurance Company, are relying on the accuracy and completeness of such information in determining eligibility, qualification, and pricing for the insurance provided. The undersigned also warrants that it has not suppressed or misstated any material facts or made any misleading representations. If the information provided in this Application should change between thedate of the Application and the effective date of the policy, the undersigned warrants that he or she will immediately report suchchanges to the Insurer. Completing and signing this Application does not bind the undersigned to purchase this insurance, nor does it bind coverage. Coverage will not be bound, nor will a policy be issued, until the applicant signifies acceptance of the company's premium quotation.

(For Montana only, the word "warrants" in the paragraph above is replaced with "represents.")

By signing below, you consent to the receipt of electronic notices and documents (collectively, "Documents"). Documents include any notice or document required as part of an insurance transaction or that is to serve as evidence of coverage. Notwithstanding the previous information, you may request at any time to have a Document sent to you in paper form also. You may also withdraw your consent at any time. Upon information and belief, the only software/hardware requirements for you to access a Document are a valid email address and the ability to open Documents in various formats. You can request a paper copy of a Document withdraw your consent, and/or notify us of a problem opening a Document, by contacting our support team at: LSS@medmarc.com.

Authorized Signature:	Date:
Print Name:	
Title:	
Email:	
If you are electronically submitting this document, apply your electronic signature to this form by check Acceptance box below. By doing so, you agree that your use of a key pad, mouse, or other device to ch Acceptance box constitutes your signature, acceptance, and agreement as if actually signed by you in vand effect as a signature affixed by hand. Electronic Signature and Acceptance - Authorized Signature	eck the Electronic Signature and

Please return your signed application using one of the following:

Fax: (703) 652-1389

Email or click Submit: apps@medmarc.com

Mailing: 4795 Meadow Wood Lane, Suite 335 West, Chantilly, VA 20151



PCOR EONR Rev. 11/11/22 Page **13** of 13